Stock Events

Stock Events

Annexon 

$4.05
43
+$0.04+1%Friday 19:59
+$0.04+0.94%Friday 23:36After hours

Statistics

Day High
4.06
Day Low
4.05
52W High
7.18
52W Low
2.54
Volume
87,400
Avg. Volume
-
Mkt Cap
767.8M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

Nov 16Expected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-0.37
-0.32
-0.28
-0.23
Expected EPS
-0.28
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-208.55MNet Income

Analyst Ratings

$18.00Average Price Target
The highest estimate is ⁦25.00⁩.
From 5 ratings within the last 6 months. This is not an investment recommendation.
Buy
60%
Hold
40%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ANNX. It's not an investment recommendation.
Amazon
8
AMZN
Tesla
7
TSLA
NVIDIA
7
NVDA
AMD
7
AMD

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Biogen
BIIB
Mkt Cap32.49B
Biogen has a strong presence in neurodegenerative diseases, directly competing with Annexon's pipeline in neurological disorders.
Roche
RHHBY
Mkt Cap334.28B
Roche, with its strong portfolio in neurology and ophthalmology, competes in areas targeted by Annexon's complement system-focused therapies.
Novartis
NVS
Mkt Cap268B
Novartis has a broad portfolio that includes treatments for neurological conditions, making it a competitor in the neurodegeneration space.
Regeneron Pharmaceuticals
REGN
Mkt Cap75.69B
Regeneron Pharmaceuticals competes in the space of ophthalmology and neurology, areas of interest for Annexon.
Astrazeneca
AZN
Mkt Cap243.34B
AstraZeneca, with its acquisition of Alexion Pharmaceuticals, competes in the development of drugs for rare diseases, overlapping with Annexon's focus areas.
Ionis Pharmaceuticals
IONS
Mkt Cap7.24B
Ionis Pharmaceuticals specializes in RNA-targeted drug discovery, including for neurological diseases, making it a competitor to Annexon.
Arbutus Biopharma
ABUS
Mkt Cap881.57M
Arbutus Biopharma focuses on developing a cure for chronic hepatitis B virus, which involves immune system modulation, indirectly competing with Annexon's complement-targeted approach.

About

Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502, for Oral small molecule; and ANX009, for systemic autoimmune diseases.
Show More
CEO
Douglas E. Love
Employees
92
Country
United States
ISIN
US03589W1027

Listings

BOATS
BOATS
ANNX.BOATS
XNAS
US
ANNX

0 Comments

Share your thoughts

FAQs

What is Annexon stock price today?▼
The current price of ANNX is $4.05 USD — it has increased by +1% in the past 24 hours. Watch Annexon stock price performance more closely on the chart.
What is Annexon stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Annexon stocks are traded under the ticker ANNX.
Is Annexon stock price growing?▼
ANNX stock has risen by +9.46% compared to the previous week, the month change is a -3.34% fall, over the last year Annexon has showed a +28.16% increase.
What is Annexon market cap?▼
Today Annexon has the market capitalization of 767.8M
When is the next Annexon earnings date?▼
Annexon is going to release the next earnings report on November 16, 2026.
What were Annexon earnings last quarter?▼
ANNX earnings for the last quarter are -0.28 USD per share, whereas the estimation was -0.24 USD resulting in a -17.23% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Annexon revenue for the last year?▼
Annexon revenue for the last year amounts to 0 USD.
What is Annexon net income for the last year?▼
ANNX net income for the last year is -208.55M USD.
How many employees does Annexon have?▼
As of November 2, 2026, the company has 92 employees.
In which sector is Annexon located?▼
Annexon operates in the Health & Wellness sector.
When did Annexon complete a stock split?▼
Annexon has not had any recent stock splits.
Where is Annexon headquartered?▼
Annexon is headquartered in BRISBANE, United States.